摘要
Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for the treatment of advanced non-small cell lung cancer (NSCLC) with MET 14 exon skipping mutation. Additionally, many studies showed that MET TKIs were equally effective in patients with advanced solid tumors with MET gene amplification or MET protein overexpression. Several relevant registered clinical studies are in progress. The most common adverse reactions (ARs) due to savolitinib administration are nausea, vomiting, peripheral edema, pyrexia, and hepatotoxicity. This consensus was developed through two rounds of extensive national surveys involving multidisciplinary experts in China, aiming to guide clinicians to prevent and treat various ARs scientifically, and improve the efficacy of the drug and the quality of life of patients.
学科与关键词
- A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 MutationLu, S.; Yu, Y.; Guo, Q.; Li, Y.; Zhong, D.; Gu, L.; Fang, J.; Han, S.; Pan, P.; Deng, P.; Liu, B.; Wang, M.; Wu, H.; Gao, F.; Lin, W.; Li, J.; Lv, D.; He, S.; Liu, Z.; Pan, C.; Li, J.; Tian, Y.; Yang, N.; Zhang, Y.; Liu, C.; Zhu, X.; Song, Q.; Yu, J.; Fan, S.; Ren, Y.; Shi, M.; Su, W.被引 1
- Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
- SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLCZhou, Q.; Li, J.; Wang, J.; Yang, L.; Fang, J.; Dong, X.; Yi, T.; Min, X.; Xu, F.; Chen, J.; Zhong, D.; Bai, J.; Liu, L.; Zeng, A.; Tang, J.; Wu, H.; Luo, X.; Yu, J.; Su, W.; Wu, Y. -L.
